Steroid sulfatase (STS) is an attractive target for a range of oestrogen- and androgen-dependent diseases. In search of novel chemotypes of STS inhibitors, we had previously identified nortropinyl-arylsulfonylureas 1; however, while these compounds were good inhibitors of purified STS (lowest K(i)=76 nM), they showed only weak inhibition of STS activity in cells (lowest IC(50) around 2 microM). Extended structure-activity relationship studies involving modification of the phenylacetyl side chain and replacement of the nortropine element by simpler scaffolds led to the discovery of N-acyl arylsulfonamides, more specifically N-(Boc-piperidine-4-carbonyl)-benzenesulfonamides, as STS inhibitors, some of which exhibit improved cellular potency (...
Inhibitors of sulfatase-2 are putative anticancer agents, but the discovery of potent small molecule...
The use of inhibitors in the treatment of hormone dependent breast is discussed. Particular emphasis...
The use of enzyme inhibitors in the treatment of patents with hormone-dependant breast cancer is dis...
Steroid sulfatase (STS) has recently emerged as a drug target for management of hormone-dependent ma...
AbstractA series of new arylamide derivatives possessing terminal sulfonate or sulfamate moieties wa...
A series of new arylamide derivatives possessing terminal sulfonate or sulfamate moieties was design...
Steroid sulfatase (STS) is an attractive target for the potential therapy of a number of estrogen- a...
The steroid sulfatase (STS) enzyme plays a pivotal role in the formation of biologically active ster...
Steroid sulphatase is an emerging drug target for the endocrine therapy of hormone-dependent disease...
The purpose of this review article is to provide an overview of recent achievements in the synthesis...
Steroid sulfatase (STS) is considered to be one of the key enzymes contributing to the development o...
Enzyme steroid sulfatase (STS) is considered as a promising therapeutic target for the treatment of ...
Two new piperazinyl-ureido single ring aryl sulfamate-based inhibitor series were designed against t...
Synthetic routes to potent bicyclic nonsteroidal sulfamate-based active-site-directed inhibitors of ...
Two new piperazinyl-ureido single ring aryl sulfamate-based inhibitor series were designed against t...
Inhibitors of sulfatase-2 are putative anticancer agents, but the discovery of potent small molecule...
The use of inhibitors in the treatment of hormone dependent breast is discussed. Particular emphasis...
The use of enzyme inhibitors in the treatment of patents with hormone-dependant breast cancer is dis...
Steroid sulfatase (STS) has recently emerged as a drug target for management of hormone-dependent ma...
AbstractA series of new arylamide derivatives possessing terminal sulfonate or sulfamate moieties wa...
A series of new arylamide derivatives possessing terminal sulfonate or sulfamate moieties was design...
Steroid sulfatase (STS) is an attractive target for the potential therapy of a number of estrogen- a...
The steroid sulfatase (STS) enzyme plays a pivotal role in the formation of biologically active ster...
Steroid sulphatase is an emerging drug target for the endocrine therapy of hormone-dependent disease...
The purpose of this review article is to provide an overview of recent achievements in the synthesis...
Steroid sulfatase (STS) is considered to be one of the key enzymes contributing to the development o...
Enzyme steroid sulfatase (STS) is considered as a promising therapeutic target for the treatment of ...
Two new piperazinyl-ureido single ring aryl sulfamate-based inhibitor series were designed against t...
Synthetic routes to potent bicyclic nonsteroidal sulfamate-based active-site-directed inhibitors of ...
Two new piperazinyl-ureido single ring aryl sulfamate-based inhibitor series were designed against t...
Inhibitors of sulfatase-2 are putative anticancer agents, but the discovery of potent small molecule...
The use of inhibitors in the treatment of hormone dependent breast is discussed. Particular emphasis...
The use of enzyme inhibitors in the treatment of patents with hormone-dependant breast cancer is dis...